引用本文:张 锐,王赞鑫,庄贤勉,张 文,刘海兵,陈白浪,姚诗华,李建峰,魏民新.机器人辅助二尖瓣置换术治疗二尖瓣病变的临床疗效及安全性分析[J].中国临床新医学,2024,17(3):272-276.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 169次   下载 290 本文二维码信息
码上扫一扫!
分享到: 微信 更多
机器人辅助二尖瓣置换术治疗二尖瓣病变的临床疗效及安全性分析
张 锐,王赞鑫,庄贤勉,张 文,刘海兵,陈白浪,姚诗华,李建峰,魏民新
香港大学深圳医院心脏大血管外科,深圳 518040
摘要:
[摘要] 目的 分析机器人辅助二尖瓣置换术治疗二尖瓣病变的临床疗效及安全性。方法 回顾性分析2020年7月至2023年2月在香港大学深圳医院接受手术治疗的60例二尖瓣病变患者的临床资料。其中接受机器人辅助二尖瓣置换术30例为观察组,传统正中开胸二尖瓣置换术30例为对照组,比较两组疗效结局指标、临床结局以及并发症发生情况。结果 两组转机时间、主动脉开放后并行时间、呼吸机使用时间比较差异无统计学意义(P>0.05)。观察组阻断时间、手术时间长于对照组,引流量、术中出血量少于对照组,创面愈合时间短于对照组,差异有统计学意义(P<0.05)。观察组临床结局的好转率为96.67%,对照组为93.33%,两组比较差异无统计学意义(P>0.05)。观察组并发症总发生率为13.33%,对照组为10.00%,两组比较差异无统计学意义(P>0.05)。结论 二尖瓣病变经机器人辅助二尖瓣置换术治疗能够有效改善患者的疗效结局指标,安全性较好,值得推广。
关键词:  二尖瓣病变  机器人辅助  二尖瓣置换术  临床效果  安全性
DOI:10.3969/j.issn.1674-3806.2024.03.06
分类号:R 654.2
基金项目:深圳市“三名工程”引进高层次医学团队项目(编号:SZSM202211005)
Analysis on the clinical efficacy and safety of robot-assisted mitral valve replacement for mitral lesions
ZHANG Rui, WANG Zanxin, ZHUANG Xianmian, ZHANG Wen, LIU Haibing, CHEN Bailang, YAO Shihua, LI Jianfeng, WEI Minxin
Department of Cardiovascular Surgery, the University of Hong Kong-Shenzhen Hospital, Shenzhen 518040, China
Abstract:
[Abstract] Objective To analyze the clinical efficacy and safety of robot-assisted mitral valve replacement for mitral lesions. Methods The clinical data of 60 patients with mitral lesions who received surgical treatment in the University of Hong Kong-Shenzhen Hospital from July 2020 to February 2023 were retrospectively analyzed. Among the 60 patients, 30 patients who received robot-assisted mitral valve replacement were included in the observation group and 30 patients who received traditional median sternotomy for mitral valve replacement were included in the control group. The therapeutic outcome indicators, clinical outcomes and complications were compared between the two groups. Results There was no significant difference in connecting time, time for cardiopulmonary bypass support after the aorta was opened and ventilator supporting time between the two groups(P>0.05). The aortic cross-clamp time and operation time in the observation group was longer than that in the control group, and the drainage volume and intraoperative blood loss in the observation group were less than those in the control group, and the wound healing time in the observation group was shorter than that in the control group, and the differences were statistically significant(P<0.05). The improvement rate of clinical outcome was 96.67% in the observation group and 93.33% in the control group, and there were no significant differences between the two groups(P>0.05). The total incidence of complications was 13.33% in the observation group and 10.00% in the control group, and there was no significant difference between the two groups(P>0.05). Conclusion Robot-assisted mitral valve replacement can effectively improve the therapeutic outcome indicators of the patients with mitral lesions. Its safety is relatively good and worthy of promotion.
Key words:  Mitral lesion  Robot-assisted  Mitral valve replacement  Clinical efficacy  Safety